journal
https://read.qxmd.com/read/38754959/granzyme-b-pet-imaging-for-assessment-of-disease-activity-in-inflammatory-bowel-disease
#1
JOURNAL ARTICLE
Pedram Heidari, Arvin Haj-Mirzaian, Suma Prabhu, Bahar Ataeinia, Shadi A Esfahani, Umar Mahmood
Developing a noninvasive imaging method to detect immune system activation with a high temporal resolution is key to improving inflammatory bowel disease (IBD) management. In this study, granzyme B (GZMB), typically released from cytotoxic T and natural killer cells, was targeted using PET with 68 Ga-NOTA-GZP (where GZP is β-Ala-Gly-Gly-Ile-Glu-Phe-Asp-CHO) to detect early intestinal inflammation in murine models of colitis. Methods: Bioinformatic analysis was used to assess the potential of GZMB as a biomarker for detecting IBD and predicting response to treatment...
May 16, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38754958/-177-lu-lu-dotatate-may-resensitize-neuroendocrine-tumors-to-hormonal-therapy-initial-clinical-experience-in-renal-carcinoid
#2
JOURNAL ARTICLE
Akram Al-Ibraheem, Ahmed Abdlkadir, Dhuha Al-Adhami, Ken Herrmann
No abstract text is available yet for this article.
May 16, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38754957/safety-and-efficacy-of-radiosynoviorthesis-a-prospective-canadian-multicenter-study
#3
JOURNAL ARTICLE
Mélanie Desaulniers, Michel Paquette, Stéphanie Dubreuil, Helena Senta, Éric Lavallée, J Carter Thorne, Éric Turcotte
Radiosynoviorthesis is approved in several European countries and the United States to treat refractory synovitis in many inflammatory joint diseases, such as rheumatoid arthritis, spondyloarthropathies, and other arthritic joint diseases. No radiopharmaceuticals for radiosynoviorthesis are currently approved in Canada. The aim of this Health Canada-approved trial was to demonstrate the safety and efficacy of radiosynoviorthesis. Methods: Between July 2012 and November 2017, we conducted a multicenter, prospective, interventional Canadian trial...
May 16, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38724282/assessing-response-to-psma-radiopharmaceutical-therapies-with-single-spect-imaging-at-24-hours-after-injection
#4
JOURNAL ARTICLE
Surekha Yadav, Fei Jiang, Sara Kurkowska, Rachelle Saelee, Amanda Morley, Felix Feng, Rahul Aggarwal, Courtney Lawhn-Heath, Carlos Uribe, Thomas A Hope
Understanding the relationship between lesion-absorbed dose and tumor response in 177 Lu-PSMA-617 radiopharmaceutical therapies (RPTs) remains complex. We aimed to investigate whether baseline lesion-absorbed dose can predict lesion-based responses and to explore the connection between lesion-absorbed dose and prostate-specific antigen (PSA) response. Methods: In this retrospective study, we evaluated 50 patients with 335 index lesions undergoing 177 Lu-PSMA-617 RPT, who had dosimetry analysis performed on SPECT/CT at 24 h after cycles 1 and 2...
May 9, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38724281/prognostic-value-of-99m-tc-tc-dpd-quantitative-spect-ct-in-patients-with-suspected-and-confirmed-amyloid-transthyretin-related-cardiomyopathy-and-preserved-left-ventricular-function
#5
JOURNAL ARTICLE
Federico Caobelli, Nasir Gözlügöl, Adam Bakula, Axel Rominger, Robin Schepers, Stefan Stortecky, Lukas Hunziker Munsch, Stephan Dobner, Christoph Gräni
Quantitative 99m Tc-3,3-diphosphono-1,2-propanodicarboxylic acid ([99m Tc]Tc-DPD) SPECT may be used for risk-stratifying patients with amyloid transthyretin-related cardiomyopathy (ATTR-CM). We aimed to analyze the predictive value of quantitative [99m Tc]Tc-DPD SPECT/CT in suspected and confirmed ATTR-CM according to different disease stages. Methods: The study enrolled consecutive patients with suspected ATTR-CM who were referred to a single tertiary center and underwent quantitative [99m Tc]Tc-DPD SPECT/CT allowing SUVmax and SUVpeak analysis...
May 9, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38724280/natural-history-of-myocardial-%C3%AE-v-%C3%AE-3-integrin-expression-after-acute-myocardial-infarction-correlation-with-changes-in-myocardial-blood-flow
#6
JOURNAL ARTICLE
Matthieu Dietz, Christel H Kamani, Colin Bousige, Vincent Dunet, Judith Delage, Vladimir Rubimbura, Marie Nicod Lalonde, Giorgio Treglia, Niklaus Schaefer, Wail Nammas, Antti Saraste, Juhani Knuuti, Nathan Mewton, John O Prior
Angiogenesis is an essential part of the cardiac repair process after myocardial infarction, but its spatiotemporal dynamics remain to be fully deciphered.68 Ga-NODAGA-Arg-Gly-Asp (RGD) is a PET tracer targeting αv β3 integrin expression, which is a marker of angiogenesis. Methods: In this prospective single-center trial, we aimed to monitor angiogenesis through myocardial integrin αv β3 expression in 20 patients with ST-segment elevation myocardial infarction (STEMI). In addition, the correlations between the expression levels of myocardial αv β3 integrin and the subsequent changes in 82 Rb PET/CT parameters, including rest and stress myocardial blood flow (MBF), myocardial flow reserve (MFR), and wall motion abnormalities, were assessed...
May 9, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38724279/-68-ga-fibroblast-activation-protein-inhibitor-pet-ct-improves-detection-of-intermediate-and-low-grade-sarcomas-and-identifies-candidates-for-radiopharmaceutical-therapy
#7
JOURNAL ARTICLE
Helena Lanzafame, Ilektra A Mavroeidi, Kim M Pabst, Mélanie Desaulniers, Marc Ingenwerth, Nader Hirmas, Lukas Kessler, Michael Nader, Timo Bartel, Stephan Leyser, Francesco Barbato, Martin Schuler, Sebastian Bauer, Jens T Siveke, Ken Herrmann, Rainer Hamacher, Wolfgang P Fendler
Fibroblast activation protein-α (FAP) is often highly expressed by sarcoma cells and by sarcoma-associated fibroblasts in the tumor microenvironment. This makes it a promising target for imaging and therapy. The level of FAP expression and the diagnostic value of 68 Ga-FAP inhibitor (FAPI) PET for sarcoma subtypes are unknown. We assessed the diagnostic performance and accuracy of 68 Ga-FAPI PET in various bone and soft-tissue sarcomas. Potential eligibility for FAP-targeted radiopharmaceutical therapy (FAP-RPT) was evaluated...
May 9, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38724278/deep-learning-enabled-quantification-of-99m-tc-pyrophosphate-spect-ct-for-cardiac-amyloidosis
#8
JOURNAL ARTICLE
Robert J H Miller, Aakash Shanbhag, Anna M Michalowska, Paul Kavanagh, Joanna X Liang, Valerie Builoff, Nowell M Fine, Damini Dey, Daniel S Berman, Piotr J Slomka
Transthyretin cardiac amyloidosis (ATTR CA) is increasingly recognized as a cause of heart failure in older patients, with 99m Tc-pyrophosphate imaging frequently used to establish the diagnosis. Visual interpretation of SPECT images is the gold standard for interpretation but is inherently subjective. Manual quantitation of SPECT myocardial 99m Tc-pyrophosphate activity is time-consuming and not performed clinically. We evaluated a deep learning approach for fully automated volumetric quantitation of 99m Tc-pyrophosphate using segmentation of coregistered anatomic structures from CT attenuation maps...
May 9, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38724277/relationship-between-absorbed-dose-and-response-in-neuroendocrine-tumors-treated-with-177-lu-lu-dotatate
#9
JOURNAL ARTICLE
Carl Fredrik Warfvinge, Johan Gustafsson, Daniel Roth, Jan Tennvall, Johanna Svensson, Peter Bernhardt, Anna Åkesson, Elinore Wieslander, Anna Sundlöv, Katarina Sjögreen Gleisner
Peptide receptor radionuclide therapy presents the possibility of tracing and quantifying the uptake of the drug in the body and performing dosimetry, potentially allowing individualization of treatment schemes. However, the details of how neuroendocrine tumors (NETs) respond to different absorbed doses are insufficiently known. Here, we investigated the relationship between tumor-absorbed dose and tumor response in a cohort of patients with NETs treated with [177 Lu]Lu-DOTATATE. Methods: This was a retrospective study based on 69 tumors in 32 patients treated within a clinical trial...
May 9, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38724276/diagnostic-performance-of-18-f-alf-thretide-pet-ct-in-patients-with-newly-diagnosed-prostate-cancer-using-histopathology-as-reference-standard
#10
JOURNAL ARTICLE
Jie Zang, Yun Yang, Shaoming Chen, Chao Wang, Shaohao Chen, Shun Hu, Hai Cai, Xiaodong Li, Ning Xu, Xiaoyuan Chen, Jingjing Zhang, Weibing Miao
This study aimed to assess the diagnostic value of [18 F]AlF-thretide PET/CT in patients with newly diagnosed prostate cancer (PCa). Methods: In total, 49 patients with biopsy-proven PCa were enrolled in this prospective study. All patients underwent [18 F]AlF-thretide PET/CT, and the scoring system of the PRIMARY trial was used for PET image analysis. The dosimetry evaluation of [18 F]AlF-thretide was performed on 3 patients. Pathologic examination was used as the reference standard to evaluate the location, number, size, and Gleason score of tumors, for comparison with the [18 F]AlF-thretide PET/CT results...
May 9, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38724275/determining-hemodynamically-significant-coronary-artery-disease-patient-specific-cutoffs-in-quantitative-myocardial-blood-flow-using-15-o-h-2-o-pet-imaging
#11
JOURNAL ARTICLE
Roel Hoek, Pepijn A van Diemen, Pieter G Raijmakers, Roel S Driessen, Yvemarie B O Somsen, Ruben W de Winter, Ruurt A Jukema, Jos W R Twisk, Lourens F H J Robbers, Pim van der Harst, Antti Saraste, Mark Lubberink, Jens Sörensen, Paul Knaapen, Juhani Knuuti, Ibrahim Danad
Currently, cutoffs of quantitative [15 O]H2 O PET to detect fractional flow reserve (FFR)-defined coronary artery disease (CAD) were derived from a single cohort that included patients without prior CAD. However, prior CAD, sex, and age can influence myocardial blood flow (MBF). Therefore, the present study determined the influence of prior CAD, sex, and age on optimal cutoffs of hyperemic MBF (hMBF) and coronary flow reserve (CFR) and evaluated whether cutoff optimization enhanced diagnostic performance of quantitative [15 O]H2 O PET against an FFR reference standard...
May 9, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38697673/reply-artificial-intelligence-algorithms-are-not-clairvoyant
#12
LETTER
Joyita Dutta, Vibha Balaji, Tzu-An Song
No abstract text is available yet for this article.
May 2, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38697672/-68-ga-fap-2286-pet-of-solid-tumors-biodistribution-dosimetry-and-comparison-with-18-f-fdg
#13
JOURNAL ARTICLE
Brad Kline, Surekha Yadav, Youngho Seo, Robin Cumming Ippisch, Jessa Castillo, Rahul R Aggarwal, Robin Kate Kelley, Spencer C Behr, Robert R Flavell, Courtney Lawhn-Heath, Michelle Melisko, Hope S Rugo, Victoria Wang, Sue S Yom, Patrick Ha, Fei Jiang, Thomas A Hope
Fibroblast activation protein (FAP), expressed in the tumor microenvironment of a variety of cancers, has become a target of novel PET tracers. The purpose of this report is to evaluate the imaging characteristics of 68 Ga-FAP-2286, present the first-to our knowledge-dosimetry analysis to date, and compare the agent with 18 F-FDG and FAPI compounds. Methods: Patients were administered 219 ± 43 MBq of 68 Ga-FAP-2286 and scanned after 60 min. Uptake was measured in up to 5 lesions per patient and within the kidneys, spleen, liver, and mediastinum (blood pool)...
May 2, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38697671/cerebral-18-f-fdg-pet-ct-metabolism-as-diagnostic-signature-for-central-nervous-system-toxicity-after-immune-checkpoint-blockade-cancer-treatment
#14
JOURNAL ARTICLE
Yifei Ma, Jiling Zeng, Fadian Ding, Yiwei Xu, Youlong Wang, Guanqing Zhong, Nianqi Liu, Yanqi Wang, Yiming Li, Shuqin Chen, Xiaolong Wei, Pengfei Zhu, Guangmin Jian, Yu Si Niu, Guangzhen Fu, Cantong Liu, Guiqiang Li, Xiaotong Zhou, Ao Zhang, Shangeng Weng
Our aim was to investigate probable biomarkers specific to immune-related central nervous system toxicity (CNST) in cancer patients treated with immune checkpoint inhibitors (ICI) by analysis of 18 F-FDG PET/CT images. Methods: Cancer patients receiving ICI treatment were enrolled in a multicenter observational study that analyzed regional metabolic changes before and during CNST onset from January 2020 to February 2022. In 1:1 propensity score-matched pairs, the regional SUVmean of each bilateral brain lobe of CNST patients (CNST+) was compared with that of patients who had central nervous system infections (CNSIs) and patients without CNST or CNSI (CNST-)...
May 2, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38697670/artificial-intelligence-algorithms-are-not-clairvoyant
#15
LETTER
Bradley J Beattie
No abstract text is available yet for this article.
May 2, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38697669/safety-and-efficacy-of-extended-therapy-with-177-lu-lu-psma-a-german-multicenter-study
#16
JOURNAL ARTICLE
Robert Seifert, Tugce Telli, Constantin Lapa, Mélanie Desaulniers, Turkay Hekimsoy, Wolfgang A Weber, Christian Pfob, Boris Hadaschik, Martin Bögemann, Michael Schäfers, Ken Herrmann, Kambiz Rahbar, Matthias Eiber, Wolfgang P Fendler
Prospective results have demonstrated favorable safety and efficacy of [177 Lu]Lu-PSMA radiopharmaceutical therapy for up to 6 cycles in men with metastatic castration-resistant prostate cancer. However, no systematic data are available outlining the feasibility of extended therapy beyond 6 cycles. We aim to evaluate the safety and efficacy of extended [177 Lu]Lu-PSMA radiopharmaceutical therapy in patients who have received more than 6 cycles. Methods: In total, 111 patients were included in this multicenter retrospective analysis...
May 2, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38664020/mri-and-18-f-fet-pet-for-multimodal-treatment-monitoring-in-patients-with-brain-metastases-a-cost-effectiveness-analysis
#17
JOURNAL ARTICLE
Jurij Rosen, Jan-Michael Werner, Garry S Ceccon, Elena K Rosen, Michael M Wollring, Isabelle Stetter, Philipp Lohmann, Felix M Mottaghy, Gereon R Fink, Karl-Josef Langen, Norbert Galldiks
PET using the radiolabeled amino acid O -(2-[18 F]fluoroethyl)-l-tyrosine (18 F-FET) has been shown to be of value for treatment monitoring in patients with brain metastases after multimodal therapy, especially in clinical situations with equivocal MRI findings. As medical procedures must be justified socioeconomically, we determined the effectiveness and cost-effectiveness of 18 F-FET PET for treatment monitoring of multimodal therapy, including checkpoint inhibitors, targeted therapies, radiotherapy, and combinations thereof in patients with brain metastases secondary to melanoma or non-small cell lung cancer...
April 25, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38664019/randomized-trial-of-prostate-specific-membrane-antigen-pet-ct-before-definitive-radiotherapy-for-unfavorable-intermediate-and-high-risk-prostate-cancer-psma-drt-trial
#18
JOURNAL ARTICLE
John Nikitas, Ethan Lam, Kiara Adame Booker, Wolfgang P Fendler, Matthias Eiber, Boris Hadaschik, Ken Herrmann, Nader Hirmas, Helena Lanzafame, Martin Stuschke, Johannes Czernin, Michael L Steinberg, Nicholas G Nickols, Amar U Kishan, Jeremie Calais
This multicenter randomized phase III trial (NCT04457245) evaluated the effect of performing prostate-specific membrane antigen (PSMA) PET/CT before definitive radiotherapy. Methods: Men with unfavorable intermediate- or high-risk prostate cancer were randomized 1.08:1 between receiving and not receiving a PSMA PET/CT scan before definitive radiotherapy. All other imaging modalities were allowed in the control arm. The primary endpoint was 5-y progression-free survival. Results: Fifty-four men were randomized between November 2020 and December 2021 (PSMA PET/CT, n = 25; control, n = 29)...
April 25, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38664018/-68-ga-ga-fapi-46-false-positive-uptake-after-chemotherapy-in-nonseminomatous-germ-cell-tumor-metastatic-lesions
#19
JOURNAL ARTICLE
Vinicius Ludwig, Peter George Maliha, John Shen, David Tonnelet, Steve Raman, Mark S Litwin, Jeremie Calais
No abstract text is available yet for this article.
April 25, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38664017/dose-reduction-in-pediatric-oncology-patients-with-delayed-total-body-18-f-fdg-pet-ct
#20
JOURNAL ARTICLE
Clemens Mingels, Benjamin A Spencer, Hande Nalbant, Negar Omidvari, Mehrad Rokni, Axel Rominger, Fatma Sen, Simon R Cherry, Ramsey D Badawi, Yasser G Abdelhafez, Lorenzo Nardo
Our aim was to define a lower limit of reduced injected activity in delayed [18 F]FDG total-body (TB) PET/CT in pediatric oncology patients. Methods: In this single-center prospective study, children were scanned for 20 min with TB PET/CT, 120 min after intravenous administration of a 4.07 ± 0.49 MBq/kg dose of [18 F]FDG. Five randomly subsampled low-count reconstructions were generated using ¼, ⅛, [Formula: see text], and [Formula: see text] of the counts in the full-dose list-mode reference standard acquisition (20 min), to simulate dose reduction...
April 25, 2024: Journal of Nuclear Medicine
journal
journal
20164
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.